NCT03562897 2022-07-06
Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer
Catalysis SL
Phase 2 Completed
Catalysis SL
Genexine, Inc.
Novartis
AGO Study Group
Novartis
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.